Breaking News Instant updates and real-time market news.

PTLA

Portola Pharmaceuticals

$33.73

-0.9 (-2.60%)

13:09
04/25/18
04/25
13:09
04/25/18
13:09

Portola to present new interim Phase 2 data for cerdulatinib at ASCO

Portola Pharmaceuticals announced that new interim results from the company's ongoing Phase 2a study of cerdulatinib in patients with Non-Hodgkin Lymphoma, including B-cell NHL and relapsed/refractory peripheral T-cell lymphoma, will be presented during a Poster Discussion Session at the 2018 American Society of Clinical Oncology, or ASCO, Annual Meeting, being held June 1-5. The poster will be presented on Monday, June 4, the company noted.

  • 04

    May

  • 21

    May

  • 12

    Jun

PTLA Portola Pharmaceuticals
$33.73

-0.9 (-2.60%)

03/01/18
WBLR
03/01/18
NO CHANGE
WBLR
Outperform
William Blair still expects Portola to receive accelerated approval for AndexXa
William Blair analyst Matt Phipps notes that shares of Portola Pharmaceuticals are trading lower after the company disclosed it received a communication from the FDA last Friday via fax that indicated the agency wants to discuss the potential for a randomized trial with AndexXa. The analyst says that while this is a notable change from previous guidance from the FDA related to the development of AndexXa, he does not believe it has an effect on the accelerated approval of AndexXa, which is expected May 4. Further, he points out that this has not been an issue raised by the European regulators to this point. Phipps believes a share price below $35 includes very little if any value contribution from AndexXa. The analyst continues to believe AndexXa will receive accelerated approval in the United States on May 4, leading to "significant share appreciation." He keeps an Outperform rating on Portola Pharmaceuticals
03/13/18
FBCO
03/13/18
NO CHANGE
Target $49
FBCO
Outperform
Portola Pharmaceuticals price target cut to $49 from $53 at Credit Suisse
Credit Suisse analyst Vamil Divan cut his price target on Portola Pharmaceuticals to $49 from $53, telling investors in a research note that while the company's updated AndexXa data looks "clean," he is "confused as to why the FDA has floated the possibility of requiring a randomized clinical trial so late in the AndexXa approval process." He expects investor confusion to remain in the short-term, as Portola has not been able to provide any clarity, but believes the drug should be approved given the current dataset and growing unmet medical need. Divan, who has an Outperform rating on Portola, sees an attractive risk/reward in the stock heading into this upcoming catalyst.
03/13/18
WBLR
03/13/18
NO CHANGE
WBLR
Outperform
William Blair still sees 'significant upside' potential in Portola shares
William Blair analyst Matt Phipps says that despite the positive second interim analysis of the ongoing Aneexa-4 study for the use of AndexXa in patients with acute major bleeding while taking a Factor Xa inhibitor, shares of Portola Pharmaceuticals old off sharply following comments by Gregg Stone from Columbia University Medical Center. During the discussion after the presentation, Stone mentioned the difficulty in broadly interpreting the results without a control group of patients, Phipps tells investors in a research note. The comment was particularly notable given a recent communication Portola received from the FDA mentioning a desire to discuss a randomized control trial, with no context around when such a trial may need to be completed in the review process, the analyst adds. He believes the current share price of Portola reflects a low confidence of AndexXa receiving FDA approval in May. Phipps continue to see "significant upside" to current share prices, with potential of $55 to $60 per share if AndexXa receives regulatory approval. The analyst keeps an Outperform rating on the name.
04/10/18
SBSH
04/10/18
NO CHANGE
SBSH
Portola risk/reward favorable in May 4 AndexXa PDUFA, says Citi
Citi analyst Yigal Nochomovitz sees a favorable risk/reward on shares of Portola Pharmaceuticals into the May 4 FDA action date for AndexXa. With FDA approval, the stock could nearly double, Nochomovitz tells investors in a research note. His price target is $58, which reflects 90% upside from current share levels. If AndexXa fails to gain FDA approval or is again delayed, the stock is likely worth around $24 per share after removing U.S. AndexXa sales, or 20% downside from current levels. Nochomovitz thinks FDA approval of AndexXa is "more likely than not." The analyst keeps a Buy rating on Portola Pharmaceuticals.

TODAY'S FREE FLY STORIES

VKTX

Viking Therapeutics

$20.35

9.95 (95.67%)

14:58
09/18/18
09/18
14:58
09/18/18
14:58
Recommendations
Viking Therapeutics analyst commentary  »

Viking price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Sep

  • 01

    Oct

ACHV

Achieve Life Sciences

$2.55

-0.05 (-1.92%)

14:56
09/18/18
09/18
14:56
09/18/18
14:56
Conference/Events
Achieve Life Sciences to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NFLX

Netflix

$362.55

12.31 (3.51%)

, VIA

Viacom

$33.80

0.05 (0.15%)

14:52
09/18/18
09/18
14:52
09/18/18
14:52
Hot Stocks
Netflix working on live-action version of 'Avatar: The Last Airbender' »

Netflix (NFLX) confirmed…

NFLX

Netflix

$362.55

12.31 (3.51%)

VIA

Viacom

$33.80

0.05 (0.15%)

VIAB

Viacom

$30.26

0.2 (0.67%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

  • 16

    Oct

BX

Blackstone

$37.63

0.53 (1.43%)

14:47
09/18/18
09/18
14:47
09/18/18
14:47
Conference/Events
Blackstone to host investor day »

Investor Day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Sep

  • 25

    Sep

ING

ING Group

$13.00

0.05 (0.39%)

14:46
09/18/18
09/18
14:46
09/18/18
14:46
Syndicate
Breaking Syndicate news story on ING Group »

ING Group files automatic…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CNST

Constellation Pharmaceuticals

$7.01

-0.64 (-8.37%)

14:44
09/18/18
09/18
14:44
09/18/18
14:44
Conference/Events
Constellation Pharmaceuticals management to meet with Jefferies »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Sep

  • 21

    Sep

NTDOY

Nintendo

$0.00

(0.00%)

14:41
09/18/18
09/18
14:41
09/18/18
14:41
Hot Stocks
Nintendo offering Fortnite bundle for Switch »

Nintendo of America…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KO

Coca-Cola

$46.06

-0.26 (-0.56%)

14:40
09/18/18
09/18
14:40
09/18/18
14:40
Hot Stocks
Coca-Cola acquires Australian maker of MOJO Kombucha, terms undisclosed »

The Coca-Cola Company has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Oct

SPWR

SunPower

$7.43

0.85 (12.92%)

14:35
09/18/18
09/18
14:35
09/18/18
14:35
Hot Stocks
SunPower spikes higher after receiving solar tariff exclusion »

Shares of solar solutions…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ABBV

AbbVie

$93.60

-1.77 (-1.86%)

14:35
09/18/18
09/18
14:35
09/18/18
14:35
Options
AbbVie put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SAIC

SAIC

$77.37

-0.58 (-0.74%)

14:30
09/18/18
09/18
14:30
09/18/18
14:30
Conference/Events
SAIC management to meet with Jefferies »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

CPA

Copa Holdings

$79.77

-0.23 (-0.29%)

14:29
09/18/18
09/18
14:29
09/18/18
14:29
Conference/Events
Copa Holdings to host investor day »

Investor Day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ABBV

AbbVie

$94.29

-1.08 (-1.13%)

14:29
09/18/18
09/18
14:29
09/18/18
14:29
Periodicals
Citron reiterates $60 AbbVie target, says lawsuit 'least of the problems' »

Citron Research just…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VIPS

Vipshop

$6.06

0.07 (1.17%)

14:25
09/18/18
09/18
14:25
09/18/18
14:25
Options
Vipshop call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GDEN

Golden Entertainment

$26.96

0.51 (1.93%)

14:21
09/18/18
09/18
14:21
09/18/18
14:21
Conference/Events
Golden Entertainment management to meet with Jefferies »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 21

    Sep

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

14:17
09/18/18
09/18
14:17
09/18/18
14:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

14:16
09/18/18
09/18
14:16
09/18/18
14:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ABBV

AbbVie

$96.00

0.63 (0.66%)

14:15
09/18/18
09/18
14:15
09/18/18
14:15
Hot Stocks
California Insurance Commissioner sues AbbVie alleging illegal kickbacks »

California Insurance…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PH

Parker-Hannifin

$189.44

1.99 (1.06%)

14:10
09/18/18
09/18
14:10
09/18/18
14:10
Options
Hefty premium buying in Parker Hannifin as shares spike »

Hefty premium buying in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VSM

Versum Materials

$35.69

-0.265 (-0.74%)

14:09
09/18/18
09/18
14:09
09/18/18
14:09
Conference/Events
Versum Materials management to meet with Jefferies »

Meeting to be held in Los…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

VSM

Versum Materials

$35.69

-0.265 (-0.74%)

14:08
09/18/18
09/18
14:08
09/18/18
14:08
Conference/Events
Versum Materials management to meet with Jefferies »

Meeting to be held in Los…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

SQ

Square

$87.41

0.54 (0.62%)

14:07
09/18/18
09/18
14:07
09/18/18
14:07
Periodicals
Square may offer investment and savings products, Recode says »

According to Recode, the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Sep

  • 19

    Sep

  • 20

    Sep

  • 26

    Sep

14:05
09/18/18
09/18
14:05
09/18/18
14:05
General news
NASDAQ is still pacing gains on Wall Street »

NASDAQ is still pacing…

VUZI

Vuzix

$5.95

0.1 (1.71%)

14:04
09/18/18
09/18
14:04
09/18/18
14:04
Hot Stocks
Vuzix partnering with OnCore Golf for 'enhanced ' AR experiences for golfers »

Vuzix is pleased to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

ABBV

AbbVie

$95.89

0.52 (0.55%)

14:03
09/18/18
09/18
14:03
09/18/18
14:03
Periodicals
CA regulator intervening in whistleblower suit against AbbVie, Bloomberg says »

California's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.